NanoViricides Inc. (NNVC)

[Raffis]

Rat testing doesn’t make any difference, here. This is not about species cell chirality of Remdesivir. This is about receptor protein The most important detail is that COVID Spike receptor was attracted to the NV-Cov-2-R receptor. This means the NV-Cov-2-R mechanism is effective. Remdesivir is FDA approved. And NV-Cov-2-R worked with Remdesivir, enhancing the plasma levels and reducing metabolic wasting. You can argue all you want. NV-Cov-2-R worked equal to or better than anticipated.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083867/
“Virus–receptor interactions play a key regulatory role in viral host range, tissue tropism, and viral pathogenesis. Viruses utilize elegant strategies to attach to one or multiple receptors, overcome the plasma membrane barrier, enter, and access the necessary host cell machinery. The viral attachment protein can be viewed as the “key” that unlocks host cells by interacting with the “lock”—the receptor—on the cell surface, and these lock-and-key interactions are critical for viruses to successfully invade host cells. Many common themes have emerged in virus–receptor utilization within and across virus families demonstrating that viruses often target particular classes of molecules in order to mediate these events. Common viral receptors include sialylated glycans, cell adhesion molecules such as immunoglobulin superfamily members and integrins, and phosphatidylserine receptors. The redundancy in receptor usage suggests that viruses target particular receptors or “common locks” to take advantage of their cellular function and also suggests evolutionary conservation. Due to the importance of initial virus interactions with host cells in viral pathogenesis and the redundancy in viral receptor usage, exploitation of these strategies would be an attractive target for new antiviral therapeutics.“

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765859/
“Binding affinity for a chiral drug can differ for diastereomers and between enantiomers. For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochemical information in structure libraries leading to a “coin toss” as to whether or not the “ideal” chiral structure is present.”

“The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compounds. These guidelines require that absolute stereochemistry be known for compounds with chiral centers and that this information should be established early in drug development in order that the analysis can be considered valid. From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.“